B-Raf/EGFR dual inhibitors (Guangzhou Institutes of Biomedicine and Health/University of Macau/Shenyang Pharmaceutical University)

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameB-Raf/EGFR dual inhibitors (Guangzhou Institutes of Biomedicine and Health/University of Macau/Shenyang Pharmaceutical University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1Serine/threonine-protein kinase B-raf
Therapy Area/IndicationsColorectal NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesShenyang Pharmaceutical UniversityUniversity of MacauGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A